Eli Lilly & Co. (NYSE:LLY)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.

Results 1 - 20 of 185 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Freeze703 (< 20) Submitted: 10/12/2015 3:14:25 PM : Outperform Start Price: $78.31 LLY Score: -1.61

Cramer says it's a buy under 80... so it's a buy under 80

Recs

0
Member Avatar WJJS (59.88) Submitted: 9/1/2015 3:46:15 PM : Outperform Start Price: $35.93 LLY Score: +59.07

Consistant through the years

Recs

0
Member Avatar PaperTrail (56.48) Submitted: 2/22/2015 7:55:55 AM : Underperform Start Price: $69.96 LLY Score: -13.40

Silly

Recs

0
Member Avatar afewgoodstocks11 (20.73) Submitted: 2/18/2014 6:56:52 PM : Outperform Start Price: $34.46 LLY Score: +61.74

Div. (Yield) $1.96 (3.6%)
Current Yield . . . . . 5.37%

Recs

0
Member Avatar theActuary (60.12) Submitted: 1/14/2014 8:00:24 AM : Outperform Start Price: $48.82 LLY Score: +43.59

LLY woot

Recs

0
Member Avatar knockripper (31.97) Submitted: 11/15/2013 9:20:56 AM : Outperform Start Price: $47.63 LLY Score: +45.68

Great Company, health care reform.

Recs

0
Member Avatar jmpeavler (< 20) Submitted: 8/12/2013 5:54:29 PM : Underperform Start Price: $51.92 LLY Score: -27.10

most of their drugs have gone genetic. A couple of new ones (diabetes and dementia) don't seem to be making much progress with testing. good dependable dividends.

Recs

1
Member Avatar Teacherman333 (96.31) Submitted: 6/1/2013 1:14:36 PM : Outperform Start Price: $49.86 LLY Score: +28.59

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 31.07%
Trailing PE 12.78
PB 3.92
Div yield 3.60%

Recs

1
Member Avatar 6sigmaford (< 20) Submitted: 11/15/2012 12:02:53 PM : Outperform Start Price: $41.29 LLY Score: +34.79

Diabetes will be around a long time and so will Lilly.

Recs

0

Recs

0
Member Avatar GVA1 (< 20) Submitted: 10/14/2012 9:58:32 AM : Outperform Start Price: $45.49 LLY Score: +26.38

Surprising success in Alzheimer's portfolio

Recs

0
Member Avatar TMFBiologyFool (97.48) Submitted: 10/12/2012 12:25:24 PM : Underperform Start Price: $45.13 LLY Score: -27.22

Over exuberance for Alzheimer's program.

Recs

0
Member Avatar FoolWithFive (98.95) Submitted: 7/25/2012 12:04:25 PM : Outperform Start Price: $38.36 LLY Score: +46.29

They are the heart and soul of indianapolis. This company does great things for the state of Indiana and health care!

Recs

1
Member Avatar einzling44 (22.83) Submitted: 5/15/2012 4:04:46 AM : Underperform Start Price: $36.10 LLY Score: -58.15

cap spending ahead

Recs

0
Member Avatar slih (< 20) Submitted: 1/26/2012 12:58:31 AM : Outperform Start Price: $34.42 LLY Score: +66.91

veternary products; retained corporate brainpower

Recs

0
Member Avatar fooluser17 (< 20) Submitted: 1/19/2012 2:04:19 PM : Outperform Start Price: $34.64 LLY Score: +63.81

Dividend rockstar, most numbers are good. Probably make this one 1%.

Recs

0
Member Avatar jesseangels (< 20) Submitted: 1/13/2012 7:41:59 PM : Outperform Start Price: $34.63 LLY Score: +62.31

Undervalued. Target ~50$.

Recs

0
Member Avatar guinness4life (78.87) Submitted: 12/21/2011 6:21:56 PM : Outperform Start Price: $36.02 LLY Score: +48.11

Long this. Gorgeous value stock with great dividend. I got in a few months ago. Get in the next time a drug misses approval.

Recs

0
Member Avatar Divlover (48.39) Submitted: 12/8/2011 4:09:44 PM : Outperform Start Price: $33.58 LLY Score: +61.65

Possible Alzhiemer drug in the works and a nice dividend.

Recs

0
Member Avatar SearchS (< 20) Submitted: 12/6/2011 9:27:59 PM : Outperform Start Price: $33.87 LLY Score: +62.14

Promising drugs in the pipeline...

Featured Broker Partners